摘要
以人胎脾淋巴细胞体外在rIL-2存在下诱导成LAK细胞并与rlL-2联合胸内注入,治疗7例癌性胸水患者。其中1例胸水完全消失,其余患者胸水明显减少,出现胸膜肥厚,连续观察8个月胸水未见进一步增多;胸水内肿瘤细胞也明显减少。7例患者均未出现任何不良反应。结果提示:胎脾LAK细胞与rIL-2胸腔内联合应用治疗癌性胸水有效,可延长患者生存期。
Seven Patients with malignant Pleural effusion were treated with intrapleural transfer of allogeneic LAK cells which were induced from lymphocytes of human fetal spleens in the presence of rIL-2 and rIL-2 combination.The results showed that the pleural effusion disappeared in one patient and significantly reduced without any increases during eight months follow-up after treatment in the others. The number of tumor cells in the pleural effusion was remarkably decreased. No serious side effects were observed in any of the patients. The results indicated that transfer of fetal LAK cells combined with rIL-2 in the treatment of patients with malignant pleural effusion was effective. The survival of these patients was prolonged.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
1995年第5期325-327,共3页
Chinese Journal of Clinical Oncology